|
|
|
|
|||||
|
|
|
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Avantor (NYSE:AVTR) and its peers.
The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives.
The 10 research tools & consumables stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 1.1% while next quarter’s revenue guidance was 1.3% below.
While some research tools & consumables stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.5% since the latest earnings results.
With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.
Avantor reported revenues of $1.62 billion, down 5.3% year on year. This print fell short of analysts’ expectations by 1.4%. Overall, it was a softer quarter for the company with a slight miss of analysts’ revenue estimates and a miss of analysts’ organic revenue estimates.
"Avantor's diverse portfolio, strong production capabilities, and long-standing customer relationships provide a strong foundation for sustained value creation," said Emmanuel Ligner, President and Chief Executive Officer.
Avantor delivered the slowest revenue growth of the whole group. Unsurprisingly, the stock is down 26.6% since reporting and currently trades at $11.08.
Read our full report on Avantor here, it’s free for active Edge members.
With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.
Sotera Health Company reported revenues of $311.3 million, up 9.1% year on year, outperforming analysts’ expectations by 2.6%. The business had an exceptional quarter with a solid beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ organic revenue estimates.
The market seems content with the results as the stock is up 3% since reporting. It currently trades at $17.10.
Is now the time to buy Sotera Health Company? Access our full analysis of the earnings results here, it’s free for active Edge members.
With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.
Bio-Techne reported revenues of $286.6 million, down 1% year on year, falling short of analysts’ expectations by 1.7%. It was a softer quarter as it posted a miss of analysts’ revenue estimates.
Bio-Techne delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 6.5% since the results and currently trades at $57.11.
Read our full analysis of Bio-Techne’s results here.
With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.
Bruker reported revenues of $860.5 million, flat year on year. This print surpassed analysts’ expectations by 1.8%. Zooming out, it was a satisfactory quarter as it also produced a beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Bruker had the weakest full-year guidance update among its peers. The stock is up 14.9% since reporting and currently trades at $44.73.
Read our full, actionable report on Bruker here, it’s free for active Edge members.
Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets.
Agilent reported revenues of $1.86 billion, up 9.4% year on year. This number topped analysts’ expectations by 1.5%. Overall, it was a strong quarter as it also produced a solid beat of analysts’ organic revenue estimates and a narrow beat of analysts’ revenue estimates.
Agilent scored the fastest revenue growth among its peers. The stock is down 11.4% since reporting and currently trades at $136.35.
Read our full, actionable report on Agilent here, it’s free for active Edge members.
The Fed’s interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump’s presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
StockStory’s analyst team — all seasoned professional investors — uses quantitative analysis and automation to deliver market-beating insights faster and with higher quality.
| Dec-18 | |
| Dec-18 | |
| Dec-12 | |
| Dec-11 | |
| Dec-10 | |
| Dec-09 | |
| Dec-08 | |
| Dec-04 | |
| Nov-25 | |
| Nov-19 | |
| Nov-11 | |
| Nov-10 | |
| Nov-05 | |
| Nov-03 | |
| Oct-31 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite